The impact of PLCO control arm contamination on perceived PSA screening efficacy

Cancer Causes and Control

Volumn 23, Issue 6, 2012, Pages 827-835

  Gulati, Roman ^a   Tsodikov, Alex ^b   Wever, Elisabeth M ^c   Mariotto, Angela B ^d   Heijnsdijk, Eveline A M ^c   Katcher, Jeffrey ^a   De Koning, Harry J ^c   Etzioni, Ruth ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Computer simulation; Early detection of cancer; Mortality; Prostate specific antigen; Prostatic neoplasms; Randomized controlled trial

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COMPUTER SIMULATION; EARLY DIAGNOSIS; FOLLOW UP; MASS SCREENING; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES; VIRTUAL REALITY;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 84862495438     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-9951-8     Document Type: Article

References (31)

1. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320-1328
2. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104:1-8. doi:10.1093/jnci/djr500
3. Pinsky PF, Black A, Kramer BS, Miller A, Prorok PC, Berg C (2010) Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Clin Trials 7(4):303-311. doi: 10.1177/1740774510374091
4. Berg CD (2011) The Prostate, Lung, Colorectal and Ovarian cancer screening trial: the prostate cancer screening results in context. Acta Oncol 50(Suppl 1):12-17. doi:10.3109/0284186X.2010.531283
5. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K (2011) Screening for prostate cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. doi: 10.1059/0003-4819-155-11-201112060-00375
6. Cuzick J, Edwards R, Segnan N (1997) Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 16(9):1017-1029. doi:10.1002/(SICI)1097-0258(19970515)16:9〈1017:AID-SIM508〉3.0.CO;2-V (Pubitemid 27198989)
7. Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A (2009) Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 56(4):584-591. doi:10.1016/j.eururo.2009.07.018
8. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95(12):868-878 (Pubitemid 36833878)
9. Tsodikov A, Szabo A, Wegelin J (2006) A population model of prostate cancer incidence. Stat in Med 25(16):2846-2866 (Pubitemid 44193388)
10. Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R (2010) Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics 11(4):707-719. doi:10.1093/biostatistics/kxq036
11. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Public-Use With State, Total U.S. (1969-2005), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008. Underlying mortality data provided by NCHS (www.cdc.gov/nchs)
12. Mariotto A, Etzioni R, Krapcho M, Feuer EJ (2007) Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer 109(9):1877-1886 (Pubitemid 46668554)
13. Goodman PJ, Thompson IM Jr, Tangen CM, Crowley JJ, Ford LG, Coltman CA Jr (2006) The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. J Urol 175(6): 2234-2242. doi:10.1016/S0022-5347(06)00284-9 (Pubitemid 43668561)
14. Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, Greenlee R, Gohagan JK (2007) Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial. BJU Int 99(4):775-779. doi:10.1111/j.1464-410X.2007.06708.x (Pubitemid 46439580)
15. Grubb RL 3rd, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabie JE, Levin DL, Chia D, Kramer BS, Reding DJ, Church TR, Yokochi LA, Kvale PA, Weissfeld JL, Urban DA, Buys SS, Gelmann EP, Ragard LR, Crawford ED, Prorok PC, Gohagan JK, Berg CD, Andriole GL (2008) Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 102(11): 1524-1530. doi:10.1111/j.1464-410X.2008.08214.x
16. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J (2006) Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 175(5):1605-1612
17. Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, De Koning HJ (2010) Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst 102(5):352-355
18. Chefo S, Tsodikov A (2009) Stage-specific cancer incidence: an artificially mixed multinomial logit model. Stat Med 28(15): 2054-2076
19. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-1319
20. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK (2000) Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control Clin Trials 21(6 Suppl):273S-309S
21. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston DA, Chen M (2000) A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 163(1):152-157
22. Presti JCJ, Chang JJ, Bhargava V, Shinohara K (2000) The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 163(1):163-166 (discussion 166-167)
23. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spangberg A, Palmgren J, Steineck G, Adami HO, Johansson JE (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708-1717. doi:10.1056/NEJMoa1011967
24. Wever EM, Draisma G, Heijnsdijk EA, de Koning HJ (2011) How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening. Med Decis Making. doi:10.1177/0272989X10396717
25. R Development Core Team (2011) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
26. Wickham H (2009) ggplot2: elegant graphics for data analysis. Springer, New York
27. Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, Gelmann E, Schoen RE, Buys S, Hayes RB, Berg CD (2007) Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. Am J Epidemiol 165(8):874-881. doi:10.1093/aje/kwk075 (Pubitemid 46536660)
28. Cetin K, Beebe-Dimmer JL, Fryzek JP, Markus R, Carducci MA (2010) Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the surveillance, epidemiology, and end results program. Urology 75(6):1396-1404. doi:10.1016/j.urology.2009.07.1360
29. Schröder FH, Roobol MJ (2010) ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol 58(1):46-52. doi:10.1016/j.eururo.2010.03.033
30. Studer UE, Collette L (2010) What can be concluded from the ERSPC and PLCO trial data? Urol Oncol 28(6):668-669. doi: 10.1016/j.urolonc.2010.03.011
31. Croswell JM, Kramer BS, Crawford ED (2011) Screening for prostate cancer with PSA testing: current status and future directions. Oncology 25(6):452-460 (463)